COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03308357
Recruitment Status : Unknown
Verified October 2017 by Mark Ward, The Alfred.
Recruitment status was:  Not yet recruiting
First Posted : October 12, 2017
Last Update Posted : October 13, 2017
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Mark Ward, The Alfred

Brief Summary:

The measurement of serum concentrations of infliximab (IFX)has now become a routine part of optimal use of that drug. Trough values are used in two situations: (a) reactively where there is loss of response to infliximab - therapeutic concentrations are indicate likely non-response to the drug, whereas low levels are associated with the chance of regaining response by increasing dosage; or (b) proactively, where dose optimisation in the maintenance phase is performed to ensure ongoing efficacy and/or cost-effective use (where high levels lead to reduction in dosage without loss of efficacy).

With the introduction of biosimilar infliximab into clinical practice, it is important to demonstrate that the biosimilar behaves similarly in the assay used as does originator infliximab to which the assays were developed. While unlikely to be different due to identical protein core, such confirmation is needed before such assays can be used in clinical practice with confidence.


  1. To compare the concentrations of biosimilar IFX (MSD-IFX) with that of originator IFX (orig-IFX) when added to serum form healthy subjects and those with IBD when measured by commonly-used commercial assays.
  2. To compare the effect of freeze-thawing and storage at 4 oC on concentrations of MSD-IFX.

Condition or disease Intervention/treatment
Inflammatory Bowel Diseases Diagnostic Test: Drug assays to measure infliximab

Detailed Description:

EXPERIMENTAL PLAN Serum This will separated from peripheral blood taken from 2 healthy subjects, 2 patients with ulcerative colitis (one with quiescent and the other with active disease), and 2 patients with Crohn's disease (one with quiescent and the other with active disease). It will be used wither fresh or freshly thawed from serum stored at -20 oC.


Two sources of infliximab will be used:

  • Orig-IFX from Janssen
  • MSD-IFX from Merck Sharp & Dome.

Preparation of simulated serum samples Fresh or thawed serum will be spiked with IFX to obtained serum at concentrations of 0, 1, 2, 4, 6, 8, 10, 12, 15 and 20 ug/ml. This range covers that seen in routine practice. These preparations will be used fresh or stored in aliquots at 4 oC or -20 oC.

Assays to be evaluated These commercially-available assay kits have been chosen on the basis that they are commonly used. They will all be used according to manufacturer's recommendations.

  • SHIKARI Q-INFLIXI from Matriks Biotech;
  • LISA TRACKER Premium from Theradiag;
  • Promonitor ELISA kit from Grifols;
  • Quantum Blue Infliximab trough level rapid test from Buhlmann. Testing protocol The two IFX molecules will be tested on the same plates in duplicate at the concentrations prepared (as above). One assay plate will be sufficient for sera from 2 individuals. One assay only will be performed on any one day.

For the direct comparisons, 3 ELISA assay kits will be required to assess 6 pairs of IFX-spiked sera. The rapid test will be performed in duplicate in a similar way.

In order to assess the effect of storing at -20 oC followed by freeze-thawing, and storage at 4 oC, sera from two subjects will be prepared at one concentration (7 ug/ml), will tested fresh and then again 7 days later after storage at the two temperatures. This will l be performed with one assay kit only (the one performing the best in the comparative studies if differences in kits emerge).

Analysis The result of MSD-IFX will be compared to those of Orig-IFX by plotting the respective curves of concentrations and visually comparing them for each assay. The percent deviation for each concentration will be calculated. The results will also be compared across assays for each IFX source and then the findings compared.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 6 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum
Estimated Study Start Date : October 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Group/Cohort Intervention/treatment
All six subjects
2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
Diagnostic Test: Drug assays to measure infliximab
See protocol

Primary Outcome Measures :
  1. Drug levels of infliximab originator and biosimilar infliximab [ Time Frame: Over the study duration (6 months) ]
    Infliximab drug levels will be measured on a range of commercially available drug assays

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients attending the inflammatory bowel disease outpatient clinics at Alfred Health. Healthy controls will be doctors attending the clinic

Inclusion Criteria:

  • Crohn's disease and ulcerative colitis, deemed to be in remission or with active disease according to validated clinical scoring indices
  • healthy controls
  • Adult patients able to give informed consent to participate

Exclusion Criteria:

  • not meeting inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03308357

Layout table for location contacts
Contact: Mark G Ward, MBBS FRACP MD +61390762223

Sponsors and Collaborators
The Alfred
Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Mark Ward, Dr, The Alfred Identifier: NCT03308357    
Other Study ID Numbers: MSD IIS-57047- GIBSON
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: October 13, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Mark Ward, The Alfred:
drug monitoring
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammatory Bowel Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents